SCHEMBL26186458

SCHEMBL26186458

O=C(Cc1cccc(F)c1Cl)Nc1cnnc(Nc2ccc(F)c(F)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANO1 Q5XXA6 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HTT P42858 1/20 0.42
▸ MAPT P10636 2/20 0.40
▸ P2RX4 Q99571 3/20 0.40
▸ KCNJ5 P48544 2/20 0.39
▸ KCNJ3 P48549 2/20 0.39
▸ RAB9A P51151 4/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36
▸ CLK2 P49760 1/20 0.36
▸ PRKX P51817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285782 1.00 ANO1 (0.46) ANO1ALDH1A1HTTMAPTP2RX4
SCHEMBL30285633 0.91 ALDH1A1 (0.49) ANO1ALDH1A1MAPTP2RX4KCNJ5
SCHEMBL26186449 0.91 ALDH1A1 (0.49) ANO1ALDH1A1MAPTP2RX4KCNJ5
SCHEMBL30285722 0.90 ANO1 (0.46) ANO1ALDH1A1MAPTP2RX4KCNJ5
SCHEMBL24173311 0.90 ANO1 (0.46) ANO1ALDH1A1MAPTP2RX4KCNJ5
SCHEMBL30285888 0.90 ANO1 (0.48) ANO1ALDH1A1MAPTP2RX4KCNJ5
SCHEMBL26186445 0.90 ANO1 (0.48) ANO1ALDH1A1MAPTP2RX4KCNJ5
SCHEMBL24173573 0.89 KCNJ5 (0.50) ANO1ALDH1A1HTTMAPTP2RX4
SCHEMBL24173312 0.89 ANO1 (0.47) ANO1ALDH1A1MAPTP2RX4KCNJ5
SCHEMBL30285757 0.89 ANO1 (0.47) ANO1ALDH1A1MAPTP2RX4KCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN claimed
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-31 — — US disclosed
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-31 — — US disclosed
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 — — US disclosed
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 — — US disclosed
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY P2RX2, P2RX5, P2RX3 ANO1 964/4885ALDH1A1 882/4885HTT 2079/4885
US-20230270729-A1 USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS P2RX2, P2RX4, P2RX5 ANO1 3464/4885ALDH1A1 2885/4885HTT 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback